Chronic Effects of Photobiomodulation With an LED Vest on Functional Capacity, Inflammatory Markers, and Muscle Perfusion in Children With Asthma
60 patients around the world
Available in Brazil
Asthma is a chronic inflammatory disease characterized by airway hyperresponsiveness,
persistent inflammation, airflow limitation, and structural airway remodeling. Pediatric
asthma remains a major public health concern due to its impact on lung development,
exercise tolerance, quality of life, and healthcare utilization. Despite advances in
pharmacological therapies, many children continue to experience symptoms, exacerbations,
and functional limitations, highlighting the need for complementary therapeutic
strategies.
Photobiomodulation therapy (PBMT) has emerged as a promising non-invasive intervention
capable of modulating biological processes through light energy absorption by cellular
photoreceptors. By stimulating mitochondrial activity and enhancing ATP production, PBMT
may reduce inflammatory responses, improve tissue repair, and optimize microcirculatory
function without inducing thermal damage. Experimental studies have demonstrated
anti-inflammatory effects associated with reductions in pro-inflammatory cytokines and
oxidative stress markers.
This randomized clinical trial aims to investigate the chronic effects of an LED
vest-based photobiomodulation intervention on functional capacity, inflammatory markers,
and pulmonary outcomes in children aged 6-17 years diagnosed with mild to moderate
asthma. Participants will be randomly assigned to either an intervention group receiving
active LED treatment or a control group receiving sham treatment through an inactive
vest. Clinical and functional assessments will include spirometry, Asthma Control Test
(ACT), GINA assessment, and the Incremental Step Test (IST) to evaluate exercise
tolerance. Additional physiological parameters may be analyzed to investigate underlying
mechanisms associated with treatment response.
The findings of this study may contribute to the development of innovative, accessible,
and clinically applicable therapeutic strategies for pediatric asthma management.
University of Nove de Julho
1Research sites
60Patients around the world
This study is for people with
Asthma
Requirements for the patient
To 17 Years
All Gender
Medical requirements
School-aged children aged 6 to 17 years, diagnosed with mild to moderate asthma, undergoing regular pharmacological treatment, clinically stable, and whose parents/legal guardians provide informed consent and who agree to participate through signed informed consent and assent forms (ICF and AF).
History of asthma exacerbation within 30 days prior to study initiation, failure to complete the questionnaires, or failure to provide signed informed consent and assent forms (ICF and AF).
Sites
Universidade Nove de Julho - UNINOVE
Av. Professor Luiz Ignácio Anhaia Mello, 1363 - Vila Prudente, São Paulo - SP, 03155-000, Brazil